Re "Brown signs 21, vetoes 12" (Capitol & California, Oct. 13): Gov. Jerry Brown vetoed legislation allowing California pharmacists to substitute biosimilars for name brand drugs and requiring pharmacists to inform providers of such. This is interesting because the Affordable Care Act called for the U.S. Food and Drug Administration to approve biosimilars for market competition. FDA responded it would ensure biosimilars posed no extra risks. Nevertheless, the bill was vetoed on the premise of prematurity and concern for safety.
What people may not realize is that major biotechnology companies are established in California and pharmacists are typically allowed to substitute generics. As a student, I perceive this as a tactic to stall approval and keep cash flowing to California-based pharmaceutical companies. Allowing California pharmacists to substitute biosimilars will make a difference towards reducing costs.
-- Chelsey Garrison, Fairfield